Chemoinformaics analysis of Phragmalin 3,30-diisobutyrate
| Molecular Weight | 700.778 | nRot | 7 |
| Heavy Atom Molecular Weight | 652.394 | nRig | 18 |
| Exact Molecular Weight | 700.31 | nRing | 8 |
| Solubility: LogS | -3.842 | nHRing | 4 |
| Solubility: LogP | 4.151 | No. of Aliphatic Rings | 7 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 98 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 50 | No. of Aromatic Carbocycles | 0 |
| nHetero | 13 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 4 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 48 | No. of Saturated Hetero Cycles | 3 |
| No. of Carbon atom | 37 | No. of Saturated Rings | 7 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 5 |
| No. of Oxygen atom | 13 | No. of Arom Bond | 5 |
| nHA | 13 | APOL | 104.222 |
| nHD | 1 | BPOL | 65.5139 |
| QED | 0.442 |
| Synth | 2.872 |
| Natural Product Likeliness | 1.509 |
| NR-PPAR-gamma | 0.979 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.006 |
| Pgp-sub | 0.081 |
| HIA | 0.02 |
| CACO-2 | -5.176 |
| MDCK | 0.0000114 |
| BBB | 0.006 |
| PPB | 0.974052 |
| VDSS | 0.575 |
| FU | 0.0302978 |
| CYP1A2-inh | 0.915 |
| CYP1A2-sub | 0.209 |
| CYP2c19-inh | 0.14 |
| CYP2c19-sub | 0.048 |
| CYP2c9-inh | 0.742 |
| CYP2c9-sub | 0.704 |
| CYP2d6-inh | 0.664 |
| CYP2d6-sub | 0.206 |
| CYP3a4-inh | 0.206 |
| CYP3a4-sub | 0.055 |
| CL | 6.219 |
| T12 | 0.912 |
| hERG | 0.01 |
| Ames | 0.556 |
| ROA | 0.089 |
| SkinSen | 0.943 |
| Carcinogencity | 0.032 |
| EI | 0.922 |
| Respiratory | 0.116 |
| NR-Aromatase | 0.952 |
| Antiviral | Yes |
| Prediction | 0.919317 |